{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.62","value":"12.4"},{"groupId":"OG001","spread":"1.63","value":"12.105"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"23"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Patients who receive a combination of Plerixafor, chemotherapy and G-CSF.\n\nPlerixafor : 240 µg/kg subcutaneous injection on the day that the ANC is \\> 1500/mm3 and on each day of apheresis for a total of 4 aphereses or the target CD34 cell dose has been reached.","id":"OG000","title":"Multiple Myeloma"},{"description":"Patients who receive a combination of Plerixafor, chemotherapy and G-CSF.\n\nPlerixafor : 240 µg/kg subcutaneous injection on the day that the ANC is \\> 1500/mm3 and on each day of apheresis for a total of 4 aphereses or the target CD34 cell dose has been reached.","id":"OG001","title":"Lymphoma"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"Within the first 4 days following the first dose of Plerixafor","title":"Average Number of Days for Engraftment (Engraftment Defined as Absolute Neutrophil Count>500)","type":"SECONDARY","unitOfMeasure":"days"}